Study of the CD161-LLT1 Immune Regulatory Axis: Evaluation of Tumor Immunity, NK Cell Function, and T Cell Responses

The CD161-LLT1 axis connects NK cells, T cells, and the tumor microenvironment, and is one of the important pathways for evaluating tumor immune regulation and immune escape. Research on this axis should not remain limited to detecting CD161 or LLT1 expression levels alone. It should also integrate cell source, spatial localization, cytotoxic function, cytokine release, exhaustion phenotype, and blocking validation for comprehensive evaluation.

Keywords: CD161; LLT1; tumor immunity; NK cells; T cell response; immune checkpoint; tumor microenvironment

1 Research Logic of the CD161-LLT1 Immune Regulatory Axis

1.1 Pathway composition

(1) CD161/KLRB1

CD161 is encoded by KLRB1 and belongs to the C-type lectin-like receptor family. It is expressed on NK cells, subsets of CD4+ T cells, CD8+ T cells, MAIT cells, Th17-like cells, and some tissue-resident T cells. It can serve as a marker for specific immune cell subsets and can also participate in regulating cell activation, tissue migration, cytokine production, and cytotoxic responses.

(2) LLT1/CLEC2D

LLT1 is encoded by CLEC2D and is an important ligand for CD161. It can be expressed on antigen-presenting cells, activated immune cells, and some tumor cells. When LLT1 is upregulated on tumor cells, B cells, dendritic cells, or myeloid cells, it may alter NK cell and T cell responses through interaction with CD161.

(3) Axis relationship

The CD161-LLT1 axis is not a fixed one-way “activating” or “inhibitory” pathway. Its function depends on cell type, tissue context, tumor type, co-stimulatory/co-inhibitory signals, and the inflammatory environment. In NK cell studies, the focus should be on whether cytotoxic function is suppressed. In T cell studies, it is necessary to distinguish whether CD161 represents effector, tissue-resident, Th17-like, chronic stimulation, or functional exhaustion features.

1.2 Decomposition of research questions

(1) Source of CD161

It should be clarified whether CD161 mainly originates from NK cells, CD8+ T cells, CD4+ T cells, MAIT cells, or tissue-resident T cells. CD161-positive cells from different sources have different functional meanings in tumor immunity, and total CD161 expression alone should not be used to explain immune status.

(2) Source of LLT1

LLT1 may originate from tumor cells, antigen-presenting cells, B cells, dendritic cells, or myeloid cells. If LLT1 is mainly located on the surface of tumor cells, it is more suitable for explaining tumor regulation of NK/T cell responses. If it is mainly located on immune cells, the regulatory network among immune cells should be further analyzed.

(3) Functional changes

Expression changes must be combined with functional readouts. Research on the CD161-LLT1 axis should at least cover cytotoxic indicators, cytokines, degranulation, proliferation, exhaustion markers, and tumor killing results to avoid directly equating surface marker changes with functional alterations.

Table 1 Core Detection Framework for CD161-LLT1 Axis Research

Research Level	Core Indicators	Recommended Methods	Interpretation Focus
Receptor expression	CD161/KLRB1	Flow cytometry, IHC, IF, qPCR, transcriptomics	Clarify expressing cell type and spatial location
Ligand expression	LLT1/CLEC2D	Flow cytometry, IHC, IF, qPCR, Western blot	Distinguish tumor cell, myeloid cell, and lymphocyte sources
NK cell function	CD107a, IFN-γ, Granzyme B, Perforin, killing rate	Flow cytometry, ELISA, cytotoxicity assays	Determine whether CD161-LLT1 affects cytotoxic function
T cell response	CD69, CD25, Ki-67, IFN-γ, TNF-α, IL-17A	Flow cytometry, ELISA, ICS, transcriptomics	Distinguish activation, proliferation, inflammatory, and exhaustion-type responses
Immunosuppression	PD-1, TIM-3, LAG-3, TIGIT, CTLA-4	Flow cytometry, IHC, transcriptomics	Determine whether CD161+ cells are accompanied by exhaustion or suppressive phenotypes
Tumor microenvironment	CD8, NKp46, CD56, CD68, MHC-I, PD-L1	Multiplex IF, IHC, spatial transcriptomics	Interpret possible axis function together with spatial proximity

2 Detection of CD161 and LLT1 Expression

2.1 CD161 expression analysis

(1) Flow cytometry

Flow cytometry is suitable for quantitative analysis of the proportion and expression intensity of CD161 in NK cells, CD8+ T cells, CD4+ T cells, and MAIT cells. Panel design should include at least CD45, CD3, CD56, CD16, CD4, CD8, TCR, or MAIT-related markers, and should be combined with live/dead staining to exclude false-positive signals caused by dead cells.

(2) Tissue localization

IHC or multiplex immunofluorescence is suitable for determining the spatial distribution of CD161+ cells in tumor nests, stroma, perivascular regions, and necrotic areas. Single-marker CD161 staining cannot confirm cell origin and is more suitable when combined with CD3, CD8, CD56, NKp46, CD103, or other tissue-residency-related markers.

(3) Transcriptomic analysis

KLRB1 expression can be used in single-cell transcriptomics or bulk RNA analysis. Single-cell data can distinguish different immune cell subsets. Bulk data reflect overall expression and are easily affected by immune infiltration proportion, so cell composition correction or immune cell deconvolution analysis should be combined.

2.2 LLT1 expression analysis

(1) Tumor cell expression

LLT1 expression on tumor cell surfaces can be detected by flow cytometry, IHC, IF, or Western blot. If high LLT1 expression occurs together with reduced NK cell killing, decreased CD107a, or reduced Granzyme B, this can support the involvement of tumor-cell-derived LLT1 in immune escape.

(2) Immune cell expression

LLT1 may also be expressed by B cells, dendritic cells, monocytes/macrophages, or activated lymphocytes. When analyzing tumor tissues, markers such as CD19, CD11c, CD14, CD68, and HLA-DR should be combined to determine the source of LLT1.

(3) Induction conditions

Inflammatory factors, tumor stimulation, Toll-like receptor signaling, or cell activation status may alter LLT1 expression. In vitro experiments may include IFN-γ, TNF-α, LPS, or tumor-conditioned medium treatment to observe whether LLT1 is inducibly upregulated.

2.3 Co-expression and spatial relationship

(1) Intercellular proximity

The CD161-LLT1 axis depends on cell contact or local interaction. Multiplex IF, spatial transcriptomics, or imaging mass cytometry can be used to determine whether CD161+ immune cells are close to LLT1+ tumor cells or antigen-presenting cells.

(2) Co-expression in the same cell

If the same cell expresses both CD161 and LLT1, interpretation should be cautious. Such results may represent autocrine/paracrine regulation or altered activation status, but may also result from antibody nonspecificity, doublet events, or cell debris adhesion. Flow cytometry singlet gating and imaging validation are required for confirmation.

(3) Functional association

Increased expression does not directly indicate pathway activation. Functional causality should be validated through blocking antibodies, gene knockdown, overexpression, co-culture, or recombinant ligand stimulation experiments.

3 CD161-LLT1 Axis in Tumor Immunity

3.1 Tumor immune escape

(1) LLT1 upregulation

Some tumor cells or tumor-associated immune cells may upregulate LLT1, allowing contact with CD161+ NK cells or T cells. If LLT1-high regions are accompanied by reduced NK cell degranulation, decreased cytotoxic molecules, or reduced tumor killing, this may suggest that this axis participates in immune escape.

(2) NK cell inhibition

NK cells rely on activating receptors such as NKG2D, DNAM-1, NKp30, NKp44, and NKp46 to recognize abnormal cells. If CD161-LLT1 signaling weakens NK cell degranulation and killing ability, it may reduce tumor immune surveillance efficiency.

(3) Remodeling of T cell responses

CD161+ T cells do not necessarily represent suppressive cells. They may display tissue-resident, inflammatory, IL-17-related, or effector memory features. When CD161+ T cells increase in tumors, PD-1, TIM-3, LAG-3, TOX, IFN-γ, GZMB, and IL-17A should be combined to determine functional status.

3.2 Differences among tumor types

(1) Solid tumors

In solid tumors, attention should focus on LLT1 expression in tumor cells, tumor-associated macrophages, and B cells, as well as whether CD161+ NK/T cells enter tumor nests. When the stromal barrier is prominent, CD161+ cells may be enriched in the stroma rather than directly adjacent to tumor cells.

(2) Hematologic tumors

In hematologic tumor samples, LLT1 expression may be associated with tumor B cells, abnormal lymphocytes, or antigen-presenting cells. Flow cytometry is more suitable for distinguishing tumor cell and immune cell sources.

(3) Immunotherapy context

In PD-1/PD-L1, CTLA-4, or NK cell therapy studies, the CD161-LLT1 axis can serve as a supplementary immune regulatory node. If CD161 or LLT1 correlates with therapeutic response, immune infiltration, or exhaustion markers, further blocking experiments can be performed to validate its therapeutic value.

Table 2 Common Result Patterns of the CD161-LLT1 Axis in Tumor Immunity

Result Pattern	Possible Interpretation	Recommended Additional Experiments
High LLT1 expression with reduced NK killing	Tumors may inhibit NK cell function through LLT1	CD161/LLT1 blocking, CD107a assay, killing assay
Increased CD161+ CD8+ T cells with high GZMB	May represent enrichment of effector-like or tissue-resident-like T cells	Co-detect IFN-γ, PD-1, CD103, TCF1
Increased CD161+ T cells with high PD-1/TIM-3	May be accompanied by exhaustion or chronic stimulation	TOX, LAG-3, functional stimulation assay
LLT1 mainly located in myeloid cells	May reflect myeloid-cell-mediated immune regulation	CD68, CD163, HLA-DR, multiplex IF
Increased KLRB1 in bulk RNA	May be driven by increased immune infiltration	Single-cell analysis or immune cell deconvolution
Enhanced killing after LLT1 blockade	Supports a functional inhibitory role of the CD161-LLT1 axis	Validate with repeated donors and different tumor cell lines

4 Evaluation of NK Cell Function

4.1 NK cell subsets

(1) CD56bright NK cells

CD56bright NK cells mainly produce cytokines and have immunoregulatory functions. They often express higher levels of regulatory receptors. Changes in CD161 in this subset should be interpreted together with IFN-γ, TNF-α, CD69, and proliferation markers.

(2) CD56dim NK cells

CD56dim NK cells mainly mediate cytotoxicity and commonly express CD16, Granzyme B, and Perforin. If the CD161-LLT1 axis affects this subset, CD107a, target cell lysis rate, and antibody-dependent cellular cytotoxicity should be prioritized.

(3) Tissue-resident NK-like cells

Some NK-like cells in tumor tissues may display tissue-resident, low-cytotoxicity, or exhaustion-like features. Markers such as CD69, CD103, CXCR6, TIGIT, and PD-1 should be included in analysis to avoid simply interpreting tissue adaptation as activation or inhibition.

4.2 Functional assays

(1) Degranulation assay

CD107a is a common readout for NK cell degranulation. After co-culturing NK cells with LLT1+ tumor cells, CD107a detection can evaluate whether the CD161-LLT1 axis affects release of cytotoxic granules.

(2) Cytotoxicity assay

LDH release, flow cytometric target cell death, and fluorescence/luminescence cytotoxicity assays can directly evaluate killing efficiency. If blocking CD161 or LLT1 increases target cell death, this more strongly supports the involvement of this axis in suppressing NK cell killing.

(3) Cytokine detection

IFN-γ, TNF-α, and GM-CSF reflect NK cell activation and inflammatory regulatory capacity. If cytotoxicity decreases but cytokines remain unchanged, CD161-LLT1 may mainly affect degranulation or killing. If both decline, broader functional suppression is suggested.

4.3 Mechanistic validation

(1) Blocking experiments

CD161 or LLT1 blocking antibodies can be used to observe whether NK cell killing, degranulation, and cytokine production recover. Blocking experiments should include isotype controls, non-blocking controls, and LLT1-negative target cell controls.

(2) Genetic manipulation

Knockdown or overexpression of CLEC2D in tumor cells, or regulation of KLRB1 in NK cells, can be used to validate directional effects. If LLT1 overexpression reduces NK cell killing and LLT1 knockdown restores killing, the evidence chain is more complete.

(3) Co-stimulatory background

NK cell function is jointly affected by IL-2, IL-12, IL-15, IL-18, and target cell ligands. CD161-LLT1 axis experiments should control cytokine stimulation intensity to avoid strong stimulation masking pathway effects.

Table 3 Indicators for NK Cell Function Evaluation

Functional Level	Recommended Indicators	Methods	Interpretation Focus
Subset composition	CD3, CD56, CD16, CD161	Flow cytometry	Distinguish CD56bright and CD56dim NK cells
Degranulation	CD107a	Flow cytometry co-culture assay	Determine whether release of cytotoxic granules is affected by LLT1
Cytotoxic molecules	Granzyme B, Perforin	Flow cytometry, Western blot, ELISA	Use together with target cell death results
Cytokines	IFN-γ, TNF-α, GM-CSF	ICS, ELISA, CBA	Determine whether functional suppression affects inflammatory output
Killing efficiency	Target cell death rate, LDH release	Flow cytometry, luminescence/fluorescence, LDH assay	Core result for functional causality validation
Inhibitory phenotype	TIGIT, PD-1, NKG2A, TIM-3	Flow cytometry	Determine whether NK cells are in an inhibitory or exhaustion-like state

5 Evaluation of T Cell Responses

5.1 CD161+ T cell subsets

(1) CD8+ T cells

CD161+ CD8+ T cells may display effector memory, tissue-resident, or chronic stimulation features. Their function should be interpreted using GZMB, PRF1, IFN-γ, PD-1, TCF1, CD103, and Ki-67, rather than defining them as suppressive or activated based only on CD161 positivity.

(2) CD4+ T cells

CD161+ CD4+ T cells are often associated with Th17-like, memory-like, or tissue inflammation-related features. IL-17A, RORγt, CCR6, IFN-γ, and TNF-α help determine their inflammatory function.

(3) MAIT cells

MAIT cells usually express high levels of CD161 and participate in mucosal immunity, antibacterial responses, and tumor immune regulation. If the sample contains a high proportion of MAIT cells, Vα7.2, MR1 tetramer, or related markers should be used to distinguish MAIT cells and avoid misinterpreting MAIT cell changes as ordinary T cell CD161 changes.

5.2 T cell functional indicators

(1) Activation and proliferation

CD69, CD25, HLA-DR, and Ki-67 can be used to evaluate T cell activation and proliferation. If CD161+ T cells also show increased Ki-67 and enhanced effector factors, they may be in an activated expansion state.

(2) Effector function

IFN-γ, TNF-α, IL-2, Granzyme B, and Perforin reflect T cell effector capacity. Whether the CD161-LLT1 axis affects T cell function should be validated through stimulation experiments, co-culture, and blocking experiments.

(3) Exhaustion and inhibition

PD-1, TIM-3, LAG-3, TIGIT, CTLA-4, and TOX can be used to evaluate exhaustion or chronic stimulation phenotypes. If CD161+ T cells simultaneously express multiple exhaustion markers and show reduced cytokines, they are more likely to represent a functionally restricted state.

5.3 Co-culture and antigen stimulation experiments

(1) Tumor co-culture

Co-culturing T cells with LLT1+ tumor cells or antigen-presenting cells can reveal the effects of the CD161-LLT1 axis on T cell activation, cytokines, and killing ability. LLT1 blocking, CD161 blocking, and ligand-negative controls are required.

(2) TCR stimulation

Anti-CD3/CD28 stimulation can be used to evaluate the maximal activation capacity of T cells. If the effect of CD161-LLT1 is weakened after strong TCR stimulation, this suggests that the axis may be more evident under weaker antigen stimulation or tumor contact conditions.

(3) Antigen-specific responses

Tumor antigen peptides, tumor cell lysates, or autologous tumor cell co-culture can be used to analyze antigen-specific T cell responses. These experiments are closer to tumor immunity scenarios but require higher sample quality and control system standards.

Table 4 Indicators for T Cell Response Evaluation

Analysis Target	Recommended Indicators	Methods	Interpretation Focus
T cell subsets	CD3, CD4, CD8, CD161	Flow cytometry, IF	Clarify which T cell type expresses CD161
MAIT cell discrimination	Vα7.2, MR1 tetramer, CD161	Flow cytometry	Avoid mixing MAIT cells into ordinary T cell interpretation
Activation status	CD69, CD25, HLA-DR	Flow cytometry	Determine short-term and sustained activation
Proliferative capacity	Ki-67, CFSE dilution	Flow cytometry	Determine T cell expansion capacity
Effector function	IFN-γ, TNF-α, IL-2, GZMB	ICS, ELISA, CBA	Use together with killing or antigen stimulation experiments
Exhaustion status	PD-1, TIM-3, LAG-3, TIGIT, TOX	Flow cytometry, IHC, transcriptomics	Determine chronic stimulation and functional restriction

6 Experimental Design and Quality Control

6.1 Sample types

(1) Tumor tissue

Tumor tissue is suitable for analyzing CD161+ immune cell infiltration, LLT1 spatial distribution, and immunosuppressive environment. Fresh tissue can be used for flow cytometry and single-cell analysis, while FFPE samples can be used for IHC or multiplex IF.

(2) Peripheral blood

Peripheral blood is suitable for dynamic monitoring of the proportion and functional status of CD161+ NK/T cells, but it cannot fully represent the tumor microenvironment. If tumor immune escape is studied, tumor tissue or tumor-infiltrating lymphocyte detection should be prioritized.

(3) In vitro co-culture

In vitro co-culture is suitable for validating functional causality of the CD161-LLT1 axis. The effector-to-target ratio, cytokine concentration, stimulation duration, and LLT1 expression level of target cells should be controlled.

6.2 Method combinations

(1) Flow cytometry as the foundation

Flow cytometry is suitable for resolving cell subsets, receptor expression, degranulation, cytokines, and exhaustion markers. In CD161-LLT1 axis research, flow cytometry is usually the core platform for function and phenotype analysis.

(2) Tissue localization as a supplement

IHC and multiplex IF can confirm whether CD161+ cells and LLT1+ cells are spatially in contact. Without spatial localization, overall expression alone cannot determine whether this axis interacts within tissues.

(3) Blocking experiments for causality validation

CD161 or LLT1 blocking is an important step in determining pathway function. If NK killing is enhanced, T cell cytokines recover, or tumor cell death increases after blockade, this more strongly demonstrates functional significance of the axis.

6.3 Key control points

(1) Antibody specificity

CD161 and LLT1 antibodies need to be validated for the intended platform. Flow cytometry antibodies, IHC antibodies, and Western blot antibodies should not be assumed to be interchangeable; positive controls, negative controls, and isotype controls should be validated separately.

(2) Gating strategy

NK cell analysis should exclude CD3+ T cells, while T cell analysis should distinguish CD4/CD8/MAIT/Treg and other subsets. LLT1 detection should exclude dead cells, doublets, and Fc receptor-mediated nonspecific binding.

(3) Functional readouts first

Expression data provide clues, while functional data are key. Research on the CD161-LLT1 axis should include at least one functional experiment, such as CD107a, cytotoxicity assay, cytokine release, blocking rescue, or genetic manipulation.

Table 5 Common Problems and Optimization Directions in CD161-LLT1 Axis Experimental Design

Problem	Common Cause	Optimization Direction
Increased CD161 expression but no functional change	CD161 only represents a subset marker, or stimulation intensity is too high	Add blocking experiments and weak-stimulation conditions
High LLT1 signal background	Antibody nonspecificity, Fc receptor binding, or dead cell interference	Add Fc blocking, live/dead staining, and negative controls
No obvious difference in NK killing assays	Inappropriate effector-to-target ratio or insufficient LLT1 expression	Optimize effector-to-target ratio and validate target-cell LLT1
Confusing T cell interpretation	CD161+ T cell composition is complex	Distinguish CD4, CD8, MAIT, and tissue-resident T cells
KLRB1 increase in bulk RNA is difficult to interpret	Changes in immune infiltration proportion	Use single-cell analysis or immune cell deconvolution
Blocking experiment ineffective	Insufficient blocking antibody concentration or pathway is not dominant	Set positive controls and combine with other checkpoint analyses
Tissue staining cannot determine interaction	Lack of spatial proximity information	Use multiplex IF or spatial analysis

7 Product Selection for CD161-LLT1 Immune Regulatory Axis Research

Table 6 Product Selection for CD161-LLT1 Immune Regulatory Axis Research

Application Module	Cat. No.	Product Name	Grade/Specification	Method/System	Application Positioning
CD161 expression detection	Ab094006	CD161 Mouse mAb	Carrier Free,ExactAb™,Azide Free,Validated,PBS Only,See COA	Antibody detection	Used for CD161 protein detection; suitable for analyzing CD161 expression in NK cells, T cells, and tumor-infiltrating immune cells
CD161 flow cytometry detection	Ab184615	CD161 Mouse mAb (FITC)	ExactAb™, Validated, Ex:498nm, Em:517nm, 0.5 mg/mL	Flow cytometry	Used for flow cytometric subdivision of CD161+ NK cells, CD161+ T cells, and MAIT-like cells
CD161 interaction validation	rp143822	Recombinant Human CD161 Protein	Animal Free,Carrier Free,Bioactive,ActiBioPure™,His Tag,≥95%(SDS-PAGE)	Recombinant protein/binding assay	Used for CD161-LLT1 binding studies, antibody binding validation, and functional experimental controls
CD161 interaction validation	rp167732	Recombinant Human CD161 Protein	Animal Free,Carrier Free,Bioactive,ActiBioPure™,Azide Free,Fc tag,≥95%(SDS-PAGE)	Recombinant protein/ligand binding assay	Used for receptor-ligand interaction, blocking validation, and protein binding experiments
CD161 gene intervention	K1462911	KLRB1 Human Pre-designed siRNA Set A		siRNA	Used to knock down CD161/KLRB1 and validate the regulatory role of CD161 in NK cell or T cell function
LLT1 gene intervention	C1460329	CLEC2D Human Pre-designed siRNA Set A		siRNA	Used to knock down LLT1/CLEC2D and validate the functional contribution of tumor-cell- or immune-cell-derived LLT1
T cell subdivision	Ab189667	CD3 Mouse mAb (APC)	ExactAb™, Validated, Ex:650nm, Em:660nm, 5 μL/test	Flow cytometry	Used to identify T cell populations and assist in distinguishing CD161+ T cells from CD161+ NK cells
T cell subdivision	Ab189661	CD3 Mouse mAb (AF488)	ExactAb™, Validated, Ex:490nm, Em:525nm, 5 μL/test	Flow cytometry	Used for T cell identification and CD161 co-expression analysis in multicolor flow cytometry panels
T cell subdivision	Ab189664	CD3 Mouse mAb (PE)	ExactAb™, Validated, Ex:565nm, Em:575nm, 5 μL/test	Flow cytometry	Used for T cell subdivision, T cell activation, and CD161+ T cell proportion detection
T cell subdivision	Ab179443	Recombinant CD3 Antibody	Carrier Free,ExactAb™,Azide Free,Validated,PBS Only,≥95%(SDS-PAGE&SEC-HPLC),See COA	Antibody detection	Used for tissue- or protein-level T cell marker detection and supporting analysis of tumor-infiltrating T cells
NK cell subdivision	Ab006503	CD56 Mouse mAb	Carrier Free,ExactAb™,Azide Free,Validated,PBS Only,See COA	Antibody detection	Used to identify NK cells and some NKT-like cells, supporting CD161+ NK cell analysis
NK cell flow cytometry detection	Ab179744	CD56 Mouse mAb (APC)	ExactAb™, Validated, Azide Free, Ex:650nm, Em:660nm, 5μL/test	Flow cytometry	Used for CD56+ NK cell subdivision and CD56bright/CD56dim subset analysis
NK cell flow cytometry detection	Ab179742	CD56 Mouse mAb (FITC)	ExactAb™, Validated, Azide Free, Ex:498nm, Em:517nm, 5μL/test	Flow cytometry	Used for NK cell identification and CD161 co-expression analysis in multicolor flow cytometry
NK cell flow cytometry detection	Ab179743	CD56 Mouse mAb (PE)	ExactAb™, Validated, Azide Free, Ex:565nm, Em:575nm, 5μL/ test	Flow cytometry	Used for NK cell proportion detection and tumor-infiltrating NK cell phenotype analysis
NK cell marker validation	rp185696	Recombinant Human NCAM-1/CD56 Protein	Animal Free,Carrier Free,Bioactive,ActiBioPure™,Azide Free,High Performance,His Tag,PBS Only,≥95%(SDS-PAGE)	Recombinant protein/control	Used as a positive control or antibody binding validation for CD56 detection systems
NK cell subdivision	Ab093973	CD16 Mouse mAb	Carrier Free, ExactAb™, Validated, See COA	Antibody detection	Used to identify CD16+ cytotoxic NK cells and support CD56dim NK cell functional analysis
NK cell flow cytometry detection	Ab181971	CD16 Mouse mAb (APC)	Validated, Ex:650nm, Em:660nm, 5 μL/test	Flow cytometry	Used for CD16+ NK cells, ADCC-related phenotype, and CD161 co-expression detection
NK cell flow cytometry detection	Ab181969	CD16 Mouse mAb (FITC)	Validated, Ex:498nm, Em:517nm, 5 μL/test	Flow cytometry	Used for NK cell subset classification and CD16 expression intensity analysis
NK cell flow cytometry detection	Ab181970	CD16 Mouse mAb (PE)	Validated, Ex:565nm, Em:575nm, 5 μL/test	Flow cytometry	Used for CD16+ NK cell proportion, cytotoxic subsets, and functional status analysis
Fc blocking/nonspecific control	Ab093991	CD16/CD32 Rat mAb	Carrier Free,ExactAb™,Azide Free,Validated,PBS Only,See COA	Fc receptor blocking/flow cytometry pretreatment	Used to reduce Fc receptor-mediated nonspecific binding in myeloid cells and tumor tissue single-cell suspensions
Myeloid source determination	Ab094025	CD163 Mouse mAb	Azide Free, Validated, Carrier Free, 1.0 mg/mL	Antibody detection	Used to identify CD163+ macrophages and assist in determining whether LLT1 originates from immunosuppressive myeloid cells
Myeloid source determination	Ab325855	Recombinant CD163 Antibody	KD Validation	Antibody detection	Used for macrophage marker detection and supporting analysis of myeloid-cell source in the tumor microenvironment
Myeloid marker detection	EJ1513450	Human Cluster Of Differentiation 163 (CD163) ELISA Kit	BioReagent	ELISA	Used to detect CD163 levels in human samples and support evaluation of tumor-associated macrophage responses
T/NK cell activation	rp181591	Recombinant Human CD69 Protein	Animal Free,Carrier Free,His Tag,PBS Only,≥95%(SDS-PAGE),See COA	Recombinant protein/control	Used for validation of CD69 detection systems and supporting T cell and NK cell activation studies
T/NK cell activation intervention	C1485344	CD69 Human Pre-designed siRNA Set A		siRNA	Used for CD69 expression regulation and supporting research on downstream activation status changes under the CD161-LLT1 axis
NK degranulation detection	Ab112729	LAMP1/CD107a Mouse mAb	See COA	Antibody detection/flow cytometry	Used for detecting NK cell and cytotoxic T cell degranulation; a core indicator for evaluating killing function
NK degranulation detection	Ab326444	LAMP1 /CD107a Antibody	KD Validation	Antibody detection	Used for CD107a/LAMP1 detection and supporting evaluation of cytotoxic granule release
NK degranulation control	rp214422	Recombinant Human LAMP-1/CD107a Protein	Animal Free,Carrier Free,Bioactive,ActiBioPure™,His Tag,PBS Only,≥95%(SDS-PAGE),See COA	Recombinant protein/control	Used for validation and positive control of CD107a detection systems
Cytotoxic molecule detection	Ab106347	Recombinant Granzyme B Antibody	ExactAb™, Validated, Carrier Free, Recombinant, 0.3 mg/mL	Antibody detection	Used to detect Granzyme B expression in NK cells and cytotoxic T cells
Cytotoxic function control	rp181293	Recombinant Human Granzyme B Protein	Animal Free,Carrier Free,Bioactive,ActiBioPure™,His Tag,PBS Only,≥95%(SDS-PAGE)	Recombinant protein/control	Used as a positive control and method validation material for Granzyme B detection systems
Cytotoxic molecule detection	Ab106372	Granzyme M Antibody	ExactAb™, Validated, Carrier Free, 0.6 mg/mL	Antibody detection	Used to supplement evaluation of NK cell granzyme profiles and cytotoxic molecule expression
Cytotoxic mechanism intervention	P1455516	Perforin-IN-2	≥99%	Perforin inhibitor	Used to validate whether perforin-dependent killing participates in functional effects of the CD161-LLT1 axis
Antigen presentation/activation status	Ab220466	HLA-DR Mouse mAb	Carrier Free,ExactAb™,Azide Free,Validated,High Performance,PBS Only,≥95%(SDS-PAGE),0.5 mg/mL	Antibody detection	Used for analyzing antigen-presenting cells, activated T cells, and immune status in the tumor microenvironment
Antigen presentation flow cytometry detection	Ab184638	HLA-DR Mouse mAb (APC)	ExactAb™, Validated, Azide Free, Ex:650nm, Em:660nm, 5 μL/test	Flow cytometry	Used to detect HLA-DR+ antigen-presenting cells and support determination of LLT1 immune cell source
Antigen presentation flow cytometry detection	Ab184637	HLA-DR Mouse mAb (PE)	Validated, Ex:565nm, Em:575nm, 5 μL/test	Flow cytometry	Used for multicolor flow cytometry analysis of HLA-DR with CD161, CD3, CD56, and other markers
IFN-γ protein detection	Ab110987	IFN-γ Mouse mAb	Carrier Free,ExactAb™,Azide Free,Validated,PBS Only,≥95%(SDS-PAGE),See COA	Antibody detection	Used to detect IFN-γ expression in NK cells and T cells and evaluate effector function output
IFN-γ flow cytometry detection	Ab191775	IFN-γ Mouse mAb (FITC)	ExactAb™, Validated, 5 μL/test	Intracellular cytokine flow cytometry	Used for ICS detection of IFN-γ and evaluation of CD161+ NK/T cell effector function
IFN-γ detection	EJ1513710	Human Interferon Gamma (IFN-γ) ELISA Kit	BioReagent	ELISA	Used to detect IFN-γ in human samples, cell supernatants, or co-culture systems
IFN-γ detection	EJ1512592	Mouse Interferon Gamma (IFN-γ) ELISA Kit	BioReagent	ELISA	Used to detect IFN-γ in mouse tumor models and evaluate anti-tumor effects of NK/T cells
IFN-γ stimulation/control	rp174267	IFN-γ1b (human recombinant)	Moligand™	Recombinant cytokine	Used for in vitro stimulation, positive control, or analysis of inflammatory regulation under LLT1 induction conditions
TNF-α detection	EJ1514669	Human Tumor Necrosis Factor Alpha (TNF-α) ELISA Kit	BioReagent	ELISA	Used to detect TNF-α in human samples or co-culture supernatants and evaluate pro-inflammatory effects of T/NK cells
TNF-α detection	EJ1511734	Mouse Tumor Necrosis Factor Alpha (TNF-α) ELISA Kit	BioReagent	ELISA	Used to detect TNF-α in mouse tumor models and support evaluation of immune effector responses
TNF-α stimulation/control	rp228949	Recombinant Human TNF-α Protein	Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,≥95%(SDS-PAGE),expressed in E. coli; See COA	Recombinant cytokine	Used for in vitro stimulation, inflammatory condition modeling, and LLT1 induction studies
T cell activation/proliferation	Ab222885	Recombinant IL-2 Receptor alpha/CD25 Antibody	Animal Free,Carrier Free,Recombinant,ExactAb™,Azide Free,Validated,High Performance,PBS Only,≥95%(SDS-PAGE),See COA	Antibody detection	Used to detect CD25/IL-2Rα and evaluate T cell activation and proliferation status
T cell activation flow cytometry	Ab230830	Recombinant IL-2 Receptor alpha/CD25 Antibody (PE)	ExactAb™,Validated,Recombinant,5 μL/test	Flow cytometry	Used to detect CD25+ activated T cells and analyze CD161+ T cell functional phenotype
IL-2 detection	EJ1514358	Human Interleukin 2 (IL-2) ELISA Kit	BioReagent	ELISA	Used to detect IL-2 secretion after T cell activation and evaluate T cell response intensity
IL-2 detection	EJ1512916	Mouse Interleukin 2 (IL-2) ELISA Kit	BioReagent	ELISA	Used to detect IL-2 in mouse tumor models or T cell co-culture systems
T/NK cell culture stimulation	rp228980	Recombinant Human IL-2 Protein	Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,His Tag,≥95%(SDS-PAGE),See COA	Cytokine stimulation	Used for NK cell and T cell culture, expansion, and functional maintenance
T/NK cell culture stimulation	rp154170	Recombinant Mouse IL-2 Protein	Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,His Tag,≥95%(SDS-PAGE),See COA	Cytokine stimulation	Used for culture and functional experiments of mouse-derived T/NK cells
Th17-like response detection	EJ1514343	Human Interleukin 17A (IL-17A) ELISA Kit	BioReagent	ELISA	Used to detect CD161+ T cell Th17-like responses and IL-17A secretion levels
Th17-like response detection	EJ1511729	Mouse Interleukin 17 A(IL-17A) ELISA Kit	BioReagent	ELISA	Used to detect IL-17A in mouse models and support evaluation of inflammatory features of CD161+ T cells
IL-17A protein detection	Ab109970	Recombinant IL-17A Antibody	Carrier Free,Recombinant,ExactAb™,Azide Free,Validated,PBS Only,See COA	Antibody detection	Used for IL-17A protein detection and supporting analysis of CD161+ CD4+ T cells or Th17-like responses
IL-17A stimulation/control	rp169639	Recombinant Human IL-17A Protein	Animal Free,Carrier Free,Bioactive,ActiBioPure™,His Tag,PBS Only,≥95%(SDS-PAGE),See COA	Recombinant cytokine	Used for IL-17A pathway stimulation, positive control, and Th17-like functional research
Th17 transcriptional feature detection	EJ1515005	Human Transcription Factor Vincristine-associated Solitary Receptor Gamma t(RORγt) ELISA Kit	BioReagent	ELISA	Used to detect RORγt in human samples and support evaluation of Th17-like differentiation features in CD161+ T cells
Th17 transcriptional feature detection	EJ1513288	Mouse Transcription Factor Retinoic Acid-related Orphan Receptor γt (RORγt) ELISA Kit	BioReagent	ELISA	Used to detect RORγt in mouse models and support evaluation of Th17-like T cell responses
RORγt mechanism intervention	S275957	SR1001	Moligand™, ≥98%	RORγt pathway intervention	Used to validate the relationship between CD161+ T cell Th17-like responses and the RORγt pathway

8 Common Questions

8.1 Is CD161 an NK cell marker or a T cell marker?

CD161 is not a marker of a single cell type. It can be expressed on NK cells, subsets of CD4+ T cells, CD8+ T cells, MAIT cells, and tissue-resident-like T cells. In research, markers such as CD3, CD56, CD4, CD8, and Vα7.2 must be combined to determine cell origin.

8.2 Does high LLT1 expression necessarily indicate tumor immunosuppression?

Not necessarily. High LLT1 expression suggests possible CD161-related regulation, but whether it causes immunosuppression requires functional validation. Only when high LLT1 expression is accompanied by reduced NK/T cell function and functional recovery after CD161-LLT1 blockade does it more strongly support an immunosuppressive role.

8.3 Are CD161+ T cells effector or suppressive cells?

This depends on tumor type, cell subset, and functional state. CD161+ T cells may have effector, tissue-resident, Th17-like, or exhaustion-like features. GZMB, IFN-γ, IL-17A, PD-1, TIM-3, TOX, and Ki-67 should be evaluated together.

8.4 Are blocking experiments necessary for studying the CD161-LLT1 axis?

Expression analysis can provide correlative clues. To prove functional effects, blocking experiments, knockdown/overexpression, or recombinant ligand stimulation experiments are recommended. Functional causality validation is key in studying this axis.

8.5 Which indicators should be prioritized for evaluating NK cell function?

CD107a degranulation, Granzyme B/Perforin, IFN-γ, and target cell death rate should be prioritized. If CD161-LLT1-mediated suppression is studied, restoration of killing after LLT1 or CD161 blockade is important evidence.

8.6 How can the source of LLT1 be determined?

The source can be determined using multicolor flow cytometry, IHC/multiplex IF, or single-cell transcriptomics. Tumor cell origin should be co-localized with tumor markers, while myeloid origin should be analyzed together with markers such as CD68, CD163, or HLA-DR.

8.7 Can the CD161-LLT1 axis serve as an immunotherapy target?

This axis has research value, but its relevance should be judged according to tumor type, expression location, functional experiments, and clinical correlation. If blocking this axis enhances NK/T cell killing and correlates with patient prognosis or immunotherapy response, it provides stronger support for its use as a candidate target.

Research on the CD161-LLT1 axis should move from expression localization to functional validation, and then be interpreted in the context of the tumor microenvironment and immunotherapy. CD161-marked immune cells are highly heterogeneous, and LLT1 may also have different cellular sources. Only by integrating cell subsets, spatial relationships, blocking experiments, and NK/T cell functional readouts can the true role of this axis in tumor immunity be determined.

For more related articles, please see below:

[1] Functional assay of cytotoxic T cells induced by specific antigens